MedTrace Logo

Study of Hepatitis Eradication Receiving Protease Inhibitor Administration

NCT03886077 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-05-01

No results posted yet for this study

Summary

This is a prospective, non-blinded cohort study that will assess the safety, tolerability, and antiviral efficacy of glecaprevir/pibrentasivir therapy given post-discharge to HCV-negative recipients of HCV infected donors. Patients who meet entry criteria will be enrolled while on the transplant waitlist. At the time of transplant, some donors will be HCV positive / NAT positive and some will not be infected. Enrolled patients who receive an HCV negative donor will serve as contemporaneous controls. All study subjects who receive an HCV positive organ will be confirmed to have acquired HCV infection and genotype will be assessed prior to treatment with therapy.

Conditions

Interventions

DRUG

glecaprevir/pibrentasivir

12 weeks of oral open label glecaprevir/pibrentasivir (Dose 3 tablets daily per package label).

Sponsors & Collaborators

  • Sentara Norfolk General Hospital

    lead OTHER

Principal Investigators

  • Amin Yehya, MD · Sentara Norfolk General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-20
Primary Completion
2024-12-20
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03886077 on ClinicalTrials.gov